Phase 1/2 Trial to Assess CRISPR Therapeutics’ CAR T Therapy in NMOSD and Related Diseases Rare Disease Advisor 23:28 lun, 21 sep
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 The Motley Fool 17:17 dum, 20 sep
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? The Motley Fool 04:25 vin, 18 sep
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It? Zacks 15:37 joi, 17 sep
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know Zacks 23:50 mar, 15 sep
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It Zacks 15:10 mar, 15 sep
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool 15:57 lun, 14 sep
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool 16:14 vin, 11 sep
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool 15:44 vin, 11 sep
CRISPR Therapeutics (CRSP) Stock Looks Fully Priced Despite Stronger Pipeline Data Simply Wall St 21:26 mar, 08 sep
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 The Motley Fool 00:05 joi, 03 sep
CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data Simply Wall St 05:18 dum, 30 aug